Somayeh Mahmoodi Khatonabadi, S. Salami, R. Mirfakhraie, Roya Atabakhshian, M. Sirati-Sabet, B. Yaghmaei, Shiva Ghafghazi, S. Ziai
{"title":"Umbelliprenin Inhibited Angiogenesis and Metastasis of MDA-MB-231 Cell Line through Downregulation of CoCl2 / EGF-Mediated PI3K / AKT / ERK Signaling","authors":"Somayeh Mahmoodi Khatonabadi, S. Salami, R. Mirfakhraie, Roya Atabakhshian, M. Sirati-Sabet, B. Yaghmaei, Shiva Ghafghazi, S. Ziai","doi":"10.30476/MEJC.2021.86492.1347","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer is known to be one of the most prevalent malignancies in women worldwide. Umbelliprenin is a naturally-occurring component derived from plant species, which has shown anti-cancer properties. The present study aimed to evaluate the effect of umbelliprenin on the PI3K / Akt / ERK signaling pathway and their products HIF-1α / VEGF in the MDA-MB-231 cell line. \nMethod: In this experimental study, the cytotoxic effect of umbelliprenin on MDA-MB-231 cells was evaluated using the MTT assay and the umbelliprenin concentrations of IC5 and IC10 were selected for the signaling pathway study. MDA-MB-231 cells were stimulated with EGF and CoCl2 and umbelliprenin IC5 and IC10 effects on gene expression and translation was studied. PI3K / Akt / mTOR / S6K / Erk1 and 2 / 4E-BP1 / HIF-1α / HIF-1β / EGFR / VEGFR and VEGF mRNA expression, and VEGF / HIF-1α proteins were evaluated employing real time PCR and western blot analysis, respectively. \nResults: The concentrations of umbelliprenin in IC10 and IC5 were 20 and 10 μM, respectively. Umbelliprenin, specifically IC10, significantly inhibited PI3K, ERK1, ERK2, Akt, mTOR, HIF1-, HIF1- mRNA, as well as HIF-1 and VEGF protein expression. \nConclusion: Our results suggested that UMB, a cytotoxic agent, inhibits PI3K / Akt / ERK signal pathway in the CoCl2 or EGF-stimulated MDA-MB-231 cells.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2021-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/MEJC.2021.86492.1347","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Breast cancer is known to be one of the most prevalent malignancies in women worldwide. Umbelliprenin is a naturally-occurring component derived from plant species, which has shown anti-cancer properties. The present study aimed to evaluate the effect of umbelliprenin on the PI3K / Akt / ERK signaling pathway and their products HIF-1α / VEGF in the MDA-MB-231 cell line.
Method: In this experimental study, the cytotoxic effect of umbelliprenin on MDA-MB-231 cells was evaluated using the MTT assay and the umbelliprenin concentrations of IC5 and IC10 were selected for the signaling pathway study. MDA-MB-231 cells were stimulated with EGF and CoCl2 and umbelliprenin IC5 and IC10 effects on gene expression and translation was studied. PI3K / Akt / mTOR / S6K / Erk1 and 2 / 4E-BP1 / HIF-1α / HIF-1β / EGFR / VEGFR and VEGF mRNA expression, and VEGF / HIF-1α proteins were evaluated employing real time PCR and western blot analysis, respectively.
Results: The concentrations of umbelliprenin in IC10 and IC5 were 20 and 10 μM, respectively. Umbelliprenin, specifically IC10, significantly inhibited PI3K, ERK1, ERK2, Akt, mTOR, HIF1-, HIF1- mRNA, as well as HIF-1 and VEGF protein expression.
Conclusion: Our results suggested that UMB, a cytotoxic agent, inhibits PI3K / Akt / ERK signal pathway in the CoCl2 or EGF-stimulated MDA-MB-231 cells.
期刊介绍:
Middle East Journal of Cancer (MEJC) is an international peer-reviewed journal which aims to publish high-quality basic science and clinical research in the field of cancer. This journal will also reflect the current status of research as well as diagnostic and treatment practices in the field of cancer in the Middle East, where cancer is becoming a growing health problem. Lastly, MEJC would like to become a model for regional journals with an international outlook. Accordingly, manuscripts from authors anywhere in the world will be considered for publication. MEJC will be published on a quarterly basis.